KDR and nonpapillary renal cell carcinoma: In a recent report, Rojas et al. studied ccRCC in a xenograft model of immunodeficient mice treated with the anti-angiogenic vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor sunitinib [39].